What Does Plus Therapeutics (PSTV) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters
A radiopharmaceutical and diagnostic biotech focused on CNS cancers. Advancing clinical trials for REYOBIQ, a rhenium-186 nanoliposome therapy, and commercializing the CNSide CSF diagnostic test.
SubscribeWhat is Plus Therapeutics (PSTV)?
Plus Therapeutics is a radiopharmaceutical and precision diagnostics company specializing in central nervous system (CNS) cancer treatment. It holds proprietary technology that delivers rhenium radioactive isotopes directly to tumors via nanoliposomes. Its lead pipeline asset, REYOBIQ™, is a radiotherapeutic that targets CNS cancers that are extremely difficult to treat, including glioblastoma (a type of brain cancer), leptomeningeal metastases, and pediatric brain tumors. The company has also already commercialized the CNSide® CSF-based diagnostic test for CNS cancers and secured insurance coverage covering 67 million lives, including Humana. Its headquarters is in Austin, Texas, and the company is listed on NASDAQ.
💰 How does it make money?
Plus Therapeutics generates revenue from commercializing the CNSide diagnostic test and aims to monetize REYOBIQ in the future.
| Pipeline | Stage | Description |
|---|---|---|
| CNSide® Diagnostic Test | Commercializing | CSF-based diagnostic test for CNS metastatic cancer; expanding insurance coverage |
| REYOBIQ™ (Re-186) | Phase 1/2 | Rhenium-186 nanoliposome radiotherapeutic targeting glioblastoma, leptomeningeal metastases, and pediatric brain tumors |
| Re-188 Nanoliposome | Preclinical / Early | Radioembolization therapeutic targeting hepatocellular carcinoma and metastatic colorectal cancer |
The current primary revenue source is the CNSide diagnostic test, with commercial expansion in 2026 as the top priority. REYOBIQ has begun treating leptomeningeal metastases patients in the ReSPECT-LM trial and has also secured FDA IND clearance for pediatric brain tumors. At this stage, revenue is limited, and the company relies on external financing.
📐 Market Cap and Company Size
The market cap is $26.6M, roughly About 0% the size of Samsung Electronics' market cap. With 28 people employees, it is a small clinical-stage biotech. There has been a NASDAQ minimum bid price compliance issue (with a 180-day grace period), but the company holds proprietary technology in the underserved medical field of rare CNS cancer radiopharmaceuticals.
📈 Plus Therapeutics Outlook and Stock Performance
1-Year Price Performance
Analyst Consensus
52-Week Price RangePlus Therapeutics' core value hinges on the clinical success of REYOBIQ and the rapid commercialization of CNSide. Its rhenium-based radioactive nanoliposome technology is a differentiated approach from existing radiopharmaceuticals, aiming to become a first mover in CNS cancers where there are currently no FDA-approved therapies.
Positive factors include indications with high unmet medical need such as leptomeningeal metastases and pediatric brain tumors, growth in diagnostic revenue from expanding CNSide insurance coverage (67 million lives), and proprietary rhenium-186 nanoliposome platform technology. Negative factors include cash burn risk and ongoing dilution concerns, NASDAQ minimum bid price compliance issues, and the long timeline to monetization given the early clinical stage.
⚔️ Core Competitive Strengths and Risks
Plus Therapeutics' strengths are its proprietary CNS cancer radiopharmaceutical technology and an integrated diagnostics-and-therapy approach, but the funding and regulatory risks typical of a small clinical-stage company are key variables.
💪 Core Competitive Strengths
⚠️ Core Risks
Competitors and Related Stocks (Beneficiaries)
Competitors include the leading radiopharmaceutical company Lantheus Holdings (LNTH), NovoCure (NVCR), which treats glioblastoma with tumor-treating electric field technology, and Fusion Pharmaceuticals (FUSN), which competes in the related radiotherapeutic and CNS cancer space.
Related stocks (beneficiaries) include large pharma companies investing in radiopharmaceutical development—Bristol-Myers Squibb (BMY), Novartis (NVS), and AstraZeneca (AZN)—which stand to benefit across the broader CNS cancer treatment ecosystem.
Compare real-time prices and valuations of competitors and related stocks in the table below.
Competitors| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
 NVCR | NovoCure Ltd | $15.51 | +1.0% | $1.8B | - | 5.3 | -43.22% | - |
 LNTH | Lantheus Holdings Inc | $100.25 | -0.1% | $6.5B | 24.2 | 5.0 | 22.21% | - |
Related stocks (beneficiaries)| Ticker | Company | Price | Change | Market Cap | P/E | PBR | ROE | Dividend Yield |
|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Co | $63.64 | -0.2% | $130.0B | 14.0 | 5.8 | 46.7% | 3.67% |
| NVS | Novartis AG ADR | $137.16 | -0.2% | $251.1B | 20.7 | 6.0 | 30.56% | 3.23% |
| AZN | Astrazeneca plc | $160.17 | +0.3% | $248.4B | 23.9 | 4.9 | 21.99% | 2.08% |
✅ Investor Checklist
Plus Therapeutics is a biotech tackling extremely difficult brain tumor treatments like glioblastoma. If successful, there is significant upside, but this is a high-risk investment with proportional risk. Having a commercialized product in CNSide is a factor that sets it apart from purely clinical-stage companies.
| Checklist | What to Confirm | Current Status |
|---|---|---|
| 🔬 REYOBIQ Clinical Trial | Are the early safety and efficacy data from the ReSPECT-LM trial positive? | ⚠️ Awaiting data release |
| 💰 CNSide Revenue | Is diagnostic revenue growing as insurance coverage expands? | ✅ 67 million covered lives |
| 🏛️ NASDAQ Compliance | Is the minimum bid price requirement being met? | ⚠️ Monitoring required |
| 💧 Cash Runway | Is there sufficient funding to reach the next clinical milestone? | ⚠️ Continuous review required |
Brain tumor drug development is a field where many attempts have failed due to the technical challenge of crossing the blood-brain barrier (BBB). Whether Plus Therapeutics' nanoliposome technology can overcome this barrier is the key to its investment value, so clinical data should be tracked closely.
In summary, Plus Therapeutics is an innovative radiopharmaceutical company targeting the unmet medical need of rare CNS cancers, but it is suitable only for investors who can tolerate the high risks typical of a small clinical-stage company. Check out Plus Therapeutics' technical indicators on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free